Summit Technologies' first-quarter results boosted by US sales
This article was originally published in Clinica
Summit Technologies' first-quarter sales have increased 94% compared with the previous year, mainly due to higher US sales of the company's excimer laser system. In March, the Massachusetts-based manufacturer of ophthalmic lasers received US FDA approval for its laser system for phototherapeutic keratectomy (PTK) to treat certain corneal pathologies (see Clinica No 646, p 20).
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.